Marksans Pharma Stock Soars 16% to New High Following Robust Q1 Earnings
Shares of Marksans Pharma surged 16% to a record high of ₹217 in Wednesday’s trading on the BSE, driven by impressive financial results for the June 2024 quarter (Q1FY25). The stock hit an intra-day peak at ₹217 and was trading at ₹216.35, up 15% at 01:49 pm, outperforming the BSE Sensex, which rose
Shares of Marksans Pharma surged 16% to a record high of ₹217 in Wednesday’s trading on the BSE, driven by impressive financial results for the June 2024 quarter (Q1FY25). The stock hit an intra-day peak at ₹217 and was trading at ₹216.35, up 15% at 01:49 pm, outperforming the BSE Sensex, which rose just 0.24%.
Strong Q1 Performance
Marksans Pharma’s stock rallied following the company’s strong quarterly results. For Q1FY25, the pharmaceutical firm reported:
- Revenue: ₹590.60 crore, marking an 18% year-on-year (YoY) increase.
- EBITDA: ₹128.4 crore, up 26% YoY, with an improved EBITDA margin of 21.7%, compared to 20.4% in the same quarter last year.
- Profit After Tax: ₹89.1 crore, a 26.5% YoY increase.
The company also saw a significant uptick in trading volumes, with a combined 16 million shares traded on the NSE and BSE, a three-fold increase over average volumes.
Market Impact
The impressive earnings performance has driven a surge in investor interest, pushing Marksans Pharma’s stock to new heights. The substantial increase in trading volume reflects strong market confidence and investor enthusiasm following the positive financial results.
Company Outlook
Marksans Pharma’s robust Q1 results suggest continued growth and strong operational efficiency. The company’s improved margins and profitability highlight its effective business strategy and solid performance in the pharmaceutical sector.
